The Experts below are selected from a list of 162 Experts worldwide ranked by ideXlab platform
Gerald M. Lemole - One of the best experts on this subject based on the ideXlab platform.
-
Comparative efficacy of cimetidine, famotidine, ranitidine, and Mylanta in postoperative stress ulcers: Gastric pH control and ulcer prevention in patients undergoing coronary artery bypass graft surgery
Gastroenterology, 1991Co-Authors: P.henri Lamothe, Edwin Rao, A.jorge Serra, Jerry Castellano, Charles L. Woronick, Kathleen W. Mcnicholas, Gerald M. LemoleAbstract:To determine the comparative efficacy of several histamine (H2)-receptor antagonists (cimetidine, famotidine, and ranitidine) and the antacid Mylanta-II (Stuart Pharmaceuticals, Wilmington, DE) in gastric pH control and the prevention of postoperative stress ulceration, a prospective, randomized study was performed in a homogeneous population of patients with elective coronary artery bypass. None of the 57 patients in the study population had a documented history of ulcer disease. There were four treatment groups, each with similar demographics (age and sex). Cimetidine-treated group consisted of 15, famotidine-treated group of 18, ranitidine-treated group of 19, and antacid-treated group of 5 patients. There was no hemodynamically significant postoperative gastrointestinal bleeding in any of the patients. When the agents were compared for efficacy of gastric pH control, statistically better pH control was found in the famotidine- and ranitidine-treated groups (P less than 0.003) than in the cimetidine-treated group (pH less than or equal to 4.0) during the 20-hour observation period. Side effects (hematologic and neurological) were noted only in the cimetidine-treated group. The results of this study indicate that in patients in postoperative intensive care, better gastric pH control, and thus prevention of gastric stress ulcers, is achieved with either famotidine or ranitidine rather than cimetidine or antacid.
Milap C. Nahata - One of the best experts on this subject based on the ideXlab platform.
-
Palatability of 14 over-the-counter antacids.
American pharmacy, 1994Co-Authors: N Bahal-o'mara, Rex W Force, Milap C. NahataAbstract:Although a number of differently flavored antacids have been introduced recently, no blinded comparative palatability evaluations have been conducted since 1977. A comparative, randomized, single-blind evaluation of over-the-counter aluminum and magnesium antacid suspensions was conducted to determine their relative palatability. Thirty healthy volunteers were asked to evaluate 14 antacids for smell, taste, texture, and aftertaste. The study found a statistically significant difference in all rated characteristics of antacids. Mylanta Cherry Creme (score 24.4 out of possible 36) and Mylanta Double Strength Cool Mint Creme (score 24.2) were ranked highest in overall palatability; Riopan Plus 2 (score 18.7) and Di-Gel Lemon Orange (score 18.0) were ranked lowest. The study concluded that the palatability of various antacid suspensions differs markedly and should be considered when selecting an antacid product.
P.henri Lamothe - One of the best experts on this subject based on the ideXlab platform.
-
Comparative efficacy of cimetidine, famotidine, ranitidine, and Mylanta in postoperative stress ulcers: Gastric pH control and ulcer prevention in patients undergoing coronary artery bypass graft surgery
Gastroenterology, 1991Co-Authors: P.henri Lamothe, Edwin Rao, A.jorge Serra, Jerry Castellano, Charles L. Woronick, Kathleen W. Mcnicholas, Gerald M. LemoleAbstract:To determine the comparative efficacy of several histamine (H2)-receptor antagonists (cimetidine, famotidine, and ranitidine) and the antacid Mylanta-II (Stuart Pharmaceuticals, Wilmington, DE) in gastric pH control and the prevention of postoperative stress ulceration, a prospective, randomized study was performed in a homogeneous population of patients with elective coronary artery bypass. None of the 57 patients in the study population had a documented history of ulcer disease. There were four treatment groups, each with similar demographics (age and sex). Cimetidine-treated group consisted of 15, famotidine-treated group of 18, ranitidine-treated group of 19, and antacid-treated group of 5 patients. There was no hemodynamically significant postoperative gastrointestinal bleeding in any of the patients. When the agents were compared for efficacy of gastric pH control, statistically better pH control was found in the famotidine- and ranitidine-treated groups (P less than 0.003) than in the cimetidine-treated group (pH less than or equal to 4.0) during the 20-hour observation period. Side effects (hematologic and neurological) were noted only in the cimetidine-treated group. The results of this study indicate that in patients in postoperative intensive care, better gastric pH control, and thus prevention of gastric stress ulcers, is achieved with either famotidine or ranitidine rather than cimetidine or antacid.
Mark Laughlin - One of the best experts on this subject based on the ideXlab platform.
-
Pharmacokinetics of Posaconazole Coadministered with Antacid in Fasting or Nonfasting Healthy Men
Antimicrobial agents and chemotherapy, 2004Co-Authors: Rachel Courtney, Elaine Radwanski, Josephine Lim, Mark LaughlinAbstract:Posaconazole is a potent broad-spectrum azole antifungal agent in clinical development for the treatment of invasive fungal infections. This study evaluated the potential for a pH-dependent pharmacokinetic interaction between posaconazole and an antacid (Mylanta), under fasting and nonfasting conditions. Twelve men completed this randomized, four-period crossover, single-dose study. Subjects received 200 mg of posaconazole following a 10-h fast, with 20 ml of Mylanta and a 10-h fast, with 20 ml of Mylanta and a high-fat breakfast, and with a high-fat breakfast alone. Antacid coadministration had no statistically significant effects on posaconazole bioavailability under fasting or nonfasting conditions. In the fasting state, antacid slightly increased the relative oral bioavailability of posaconazole by 15% (P = 0.296); in the nonfasting state, antacid decreased the relative bioavailability of posaconazole by 12% (P = 0.352). Food increased the relative oral bioavailability of posaconazole by 400% (P = 0.001). In conclusion, the effect of antacid on posaconazole exposure in the fasting or nonfasting state was small and is not considered clinically significant.
Elaine Radwanski - One of the best experts on this subject based on the ideXlab platform.
-
Pharmacokinetics of Posaconazole Coadministered with Antacid in Fasting or Nonfasting Healthy Men
Antimicrobial agents and chemotherapy, 2004Co-Authors: Rachel Courtney, Elaine Radwanski, Josephine Lim, Mark LaughlinAbstract:Posaconazole is a potent broad-spectrum azole antifungal agent in clinical development for the treatment of invasive fungal infections. This study evaluated the potential for a pH-dependent pharmacokinetic interaction between posaconazole and an antacid (Mylanta), under fasting and nonfasting conditions. Twelve men completed this randomized, four-period crossover, single-dose study. Subjects received 200 mg of posaconazole following a 10-h fast, with 20 ml of Mylanta and a 10-h fast, with 20 ml of Mylanta and a high-fat breakfast, and with a high-fat breakfast alone. Antacid coadministration had no statistically significant effects on posaconazole bioavailability under fasting or nonfasting conditions. In the fasting state, antacid slightly increased the relative oral bioavailability of posaconazole by 15% (P = 0.296); in the nonfasting state, antacid decreased the relative bioavailability of posaconazole by 12% (P = 0.352). Food increased the relative oral bioavailability of posaconazole by 400% (P = 0.001). In conclusion, the effect of antacid on posaconazole exposure in the fasting or nonfasting state was small and is not considered clinically significant.
-
Pharmacokinetic drug interaction study: administration of ceftibuten concurrently with the antacid Mylanta double- strength liquid or with ranitidine
American journal of therapeutics, 1998Co-Authors: Elaine Radwanski, A Nomeir, D Cutler, M.b. Affrime, C. C. LinAbstract:This study investigated the influence of antacid (Mylanta Double-Strength Liquid; J & J-Merck Consumer, Fort Washington, PA) and the H2 antagonist ranitidine on the pharmacokinetics of ceftibuten, a once-daily oral cephalosporin. Eighteen male volunteers received, in a randomized, three-way, crossover design, a single oral 400-mg dose of ceftibuten after an overnight fast (1) alone, (2) with antacid (60 mL), and (3) with ranitidine (after 3 days of dosing, 150 mg/12 hours). Serial blood and urine samples were collected during a 24-hour period after each administration, with a 1-week washout between treatments. Ceftibuten, and its metabolite ceftibuten-trans, were analyzed in plasma and urine by high-performance liquid chromatography. Bioavailability parameters, maximum plasma concentration and area under the plasma concentration-time curve to infinity of ceftibuten were unaffected by treatment with antacid. These parameters were somewhat higher when ceftibuten was administered with ranitidine, but they were still within the ranges seen in normal healthy volunteers. The excretion of ceftibuten was independent of treatment. The concentrations of ceftibuten-trans were low in both plasma and urine with all three treatments. It is concluded that the co-administration of antacid and ranitidine are unlikely to affect the bioavailability and antibacterial efficacy of ceftibuten.
